Paper - WANFANG MED ONLINE

You Position: Home > Paper

Liver regeneration microenvironment in liver cancer:Research progress and prospect

( views:28, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 26

DOI:: 10.11569/wcjd.v26.i26.1529

Key Word:: 肝癌;肝再生;微环境

Abstract：提出肝癌(liver cancer,LC)的肝再生微环境的新概念有助于从整体上认识和把握肝再生微环境与炎症损伤微环境、免疫调控微环境及血管新生微环境等LC微环境对LC发生发展、复发转移影响的相关机制,探讨更为全面更加有效地通过改善LC的肝再生微环境防治LC发生发展、复发转移的措施与方案,提高LC防治能力和水平.LC的肝再生微环境影响LC的发生发展、复发转移,在消灭LC细胞或组织的基础上,结合维护正常的肝再生机制和改善LC的肝再生微环境是防治LC的重要策略之一,研究多成分、多靶点、多层次、多途径、多时限地改善肝再生微环境而延缓、阻止、甚或逆转LC的发生、发展和转移的网络式作用机制是防治LC的重要研究方向之一.近些年来,中医药改善肝再生微环境防治LC的发生发展及复发转移方面的研究与应用虽取得若干进展,但如何全面准确地揭示网络式的作用机制和如何提供高级别的循证医学证据两大关键科学问题亟待通过更加全面深入地研究,重点推进,加以解决.

Reference

[1]陈艳,杨永平.中医药阻断逆转肝纤维化的现状、希望与挑战[J].2018,(4).
[2]Wei ZHANG,Xiao-Ping Chen,Wan-Guang Zhang,etc.Hepatic non-parenchymal cells and extracellular matrix participate in oval cell-mediated liver regeneration[J].2009,(5).
[3]贾永宁,季科,叶林,等.养正消积抗肿瘤作用的机制[J].2013,(5).
[4]李惠,叶庆,殷晓进,等.肝细胞肝癌血管新生的研究进展[J].2009,(4).
[5]黑振宇,王鲁,金惠铭.VEGF与原发性肝癌血管新生关系的研究进展[J].2005,(4).
[6]李瀚旻.“补肾生髓成肝”治疗肝脏病的基础及临床应用[J].2013,(6).
[7]俞映倩,管斌.扶正化瘀胶囊对慢性乙型肝炎患者血清 TGF-β1的影响[J].2015,(12).
[8]常明向,吴梅梅,李瀚旻.姜黄素联合索拉非尼增强抑制肝癌细胞HepG-2的作用及其机制[J].2016,(5).
[9]李瀚旻,晏雪生,明安萍,等.脂质体-姜黄素水溶制剂抗肝癌效应的稳定性研究[J].2006,(4).
[10]李霞,丰平,文朝阳,等.方剂槲芪散及君药槲寄生提取物对人肝癌细胞生长的抑制作用[J].2006,(20).
[11]盛庆寿,王武.中药抗肝癌血管生成作用研究进展[J].2014,(1).
[12]左婷婷,郑荣寿,曾红梅,等.中国肝癌发病状况与趋势分析[J].2015,(9).
[13].上皮间质细胞转化的分子机制及其在肿瘤转移中的作用[J].2009,(5).
[14]刘平.汇聚中西医优势互补的临床证据，提高肝胆胰疾病结合医学诊疗水平[J].2017,(5).
[15]XIA Li,Zheng-Ming Shi,Ping FENG,etc.Effect of Qi-protecting powder (Huqi San) on expression of c-jun, c-fos and c-myc in diethylnitrosamine-mediated hepatocarcinogenesis[J].2007,(31).
[16]张水艳,谷春华,高学东,等.养正消积胶囊辅助介入化疗治疗原发性肝癌的随机双盲多中心临床研究[J].2009,(8).
[17]李瀚旻,赵宾宾,高翔,等.“补肾生髓成肝”改善肝再生微环境、防治肝癌的作用及机制[J].2015,(1).
[18]张映林,周世骥,李生伟.VEGF和Notch通路在肝癌血管形成中的作用[J].2014,(3).
[19]刘国利,张锦英.医学中的混沌与混沌中的医学[J].2016,(17).
[20]薛冬英,叶军,陈蓓,等.扶正化瘀胶囊对慢性乙型肝炎血清细胞因子和炎症纤维化指标的影响[J].2008,(5).
[21]李瀚旻.神经-内分泌-免疫-肝再生调控网络[J].2014,(4).
[22]崔艳峰,祖茂衡,徐浩,等.肝细胞癌TACE术后严重并发症分析[J].2005,(1).
[23]."补肾生髓成肝"治疗肝脏病的基础与临床应用[J].2017,(23).
[24]李瀚旻.上皮-间质转型/间质-上皮转型失衡与髓失生肝[J].2012,(1).
[25]李瀚旻.髓本质研究进展[J].2015,(6).
[26]李向利,丰平,钱英,等.槲芪散及其君药槲寄生对大鼠肝癌前病变组织中促凋亡因子Omi/HtrA2表达的影响[J].2008,(4).
[27]黄果,王佑权,谭米多,等.姜黄素抗肿瘤作用机制的研究进展[J].2014,(5).
[28]王融冰,孙凤霞.中西医结合治疗常见肝胆胰疾病的现状与展望[J].2018,(4).
[29]李瀚旻.基于“补肾生髓成肝”的肝癌三级预防方案的构建与应用[J].2015,(6).
[30]文朝阳,丰平,李霞,等.槲芪散阻断肝癌前病变的机制研究[J].2006,(4).
[31]李瀚旻.从调控肝再生探讨肝纤维化的防治[J].2015,(6).
[32]张蓓,黄国贤,张亚奇,等.加味四君子汤防治肝癌介入治疗后肝储备功能损伤的临床研究[J].2004,(5).
[33]李瀚旻,晏雪生,明安萍,等.脂质体介导姜黄素抑制Bel-7402细胞增殖和诱导其凋亡的作用[J].2005,(4).
[34]Bin-Bin, Zhao,Han-Min, Li,Xiang, Gao,etc.The herbal compound "diwu yanggan" modulates liver regeneration by affecting the hepatic stem cell microenvironment in 2-acetylaminofluorene/partial hepatectomy rats.[J].2015,2015.
[35]Moslehi, Javid J.,Salem, Joe-Elie,Sosman, Jeffrey A.,etc.Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J].2018,391(10124).
[36]Hanmin, Li,Lisheng, Zhang.Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy.[J].2017,8(1).
[37]李瀚旻.中医药调控肝再生的研究进展及展望[J].2017,(15).
[38]李瀚旻.论“补肾生髓成肝”治疗法则[J].2012,(5).
[39]李瀚旻.中医药调控肝再生的基础与临床研究[J].2017,(8).
[40]van Zijl F,Kornauth C,Schneller D,etc.Epithelial-mesenchymal transition in hepatocellular carcinoma.[J].2009,5(8).
[41]Allemani, Claudia,Matsuda, Tomohiro,Di Carlo, Veronica,etc.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].2018,391(10125).
[42]Hanmin, Li,Zhihua, Ye,Xiang, Gao,etc.Diwu Yanggan capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial.[J].2018,10(5).
[43]李瀚旻.调控肝再生的研究进展及展望[J].2015,(21).
[44]M Angela, Nieto.Epithelial plasticity: a common theme in embryonic and cancer cells.[J].2013,342(6159).
[45]Hongyang Wang,Lei Chen.Tumor microenviroment and hepatocellular carcinoma metastasis.[J].2013,28(Suppl.1).
[46]冯琴,王晓柠.第二十四次全国中西医结合肝病学术会议纪要[J].2015,(6).
[47]Jianhui, Qu,Zujiang, Yu,Qin, Li,etc.Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.[J].2014,15.
[48]Zaher K. Otrock,Rami A.R. Mahfouz,Jawad A. Makarem,etc.Understanding the biology of angiogenesis: Review of the most important molecular mechanisms[J].2007,39(2).
[49]Wang,Y.-P.,Yu,G.-R.,Lee,M.-J.,etc.Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway[J].2013,58(4).
[50]Sasagawa,S.,Dong,Y.,Cheng,E.H.,etc.HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma[J].2013,123(7).
[51]Scarpino S,Cancellario D'Alena F,Di Napoli A,etc.Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis.[J].2003,199(2).
[52]Leonidas G Koniaris,Iain H McKillop,Seymour I Schwartz,etc.Liver regeneration[J].2003,197(4).
[53]Ferlay J,Shin HR,Bray F,etc.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.[J].2010,127(12).
[54]Xu J,Guo RP,Zhang SD,etc.Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection.[J].2011,117(21).
[55]Yamamoto K,Zhao G,Hisatomi A,etc.Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1.[J].2003,27(4).
[56]Sasan Roayaie,Ghalib Jibara,Parissa Tabrizian,etc.The Role of Hepatic Resection in the Treatment of Hepatocellular Cancer[J].2015,62(2).
[57]LI Ma,Bin WANG,Yuanxiong Long,etc.Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: a systematic review with meta-analysis[J].2017,(2).
[58]Raven, Alexander,Lu, Wei-Yu,Man, Tak Yung,etc.Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration[J].2017,547(Jul.20 TN.7663).
[59]Chen JG,Zhang SW.Liver cancer epidemic in China: past, present and future.[J].2011,21(1).
[60]Steven Dooley,Peter ten Dijke.TGF-β in progression of liver disease.[J].2012,347(1).
[61]Lin, Shengda,Nascimento, Elisabete M.,Gajera, Chandresh R.,etc.Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury[J].2018,556(Apr.12 TN.7700).
[62].Microcirculation of Liver Cancer, Microenvironment of Liver Regeneration, and the Strategy of Chinese Medicine[J].2016,22(3).
[63]李瀚旻, 著.中医药调控肝再生基础与临床[M].2016.
[64]Xie,G.,Diehl,A.M..Evidence for and against epithelial-to-mesenchymal transition in the liver[J].2013,305(6 Pt.1).
[65].Microenvironment of Liver Regeneration in Liver Cancer[J].2017,(7).
[66]Line,P.-D.,Shi,J.-H.,Scholz,H.,etc.RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver[J].2013,107(4).
[67]Mingxiang, Chang,Meimei, Wu,Hanmin, Li.Curcumin combined with glycyrrhetinic acid inhibits the development of hepatocellular carcinoma cells by down-regulating the PTEN/PI3K/AKT signalling pathway.[J].2017,9(12).
[68]Hezhe Lu,Jianglan Liu,Shujing Liu,etc.Exo70 Isoform Switching upon Epithelial-Mesenchymal Transition Mediates Cancer Cell Invasion[J].2013,27(5).
[69]Suh,S.-W.,Lee,K.-W.,Lee,J.-M.,etc.Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection[J].2014,60(6).
[70]Tam,W.L.,Weinberg,R.A..The epigenetics of epithelial-mesenchymal plasticity in cancer[J].2013,19(11).
[71]主编王滨, 曹贵文.介入护理学[M].2005.
[72]Sanchez A,Conner EA,Uchida K,etc.Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair[J].2004,101(13).
[73]常明向,吴梅梅,李瀚旻.姜黄素与甘草次酸联用对肝癌HepG-2细胞增殖的抑制作用[J].2017,(1).